MK 3745 (Merck Inc) moves into Phase III for Melanoma
Merck Inc., announced additional data for MK-3475 (lambrolizumab), an investigational anti-PD-1 immunotherapy, in patients with advanced Melanoma that showed an estimated overall survival rate of 81 percent at one year across all MK-3475 monotherapy doses evaluated. This is the first time overall survival data have been presented from the cohort of 135 patients with advanced melanoma enrolled in Merck's ongoing Phase IB clinical trial (PN 001) for MK-3475. Researchers presented the findings today in an oral plenary session at the 10th International Congress of the Society for Melanoma Research in Philadelphia.
A Phase III registration trial of MK-3475 versus ipilimumab in ipilimumab-na�ve patients with advanced Melanoma is ongoing.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.